Intellia Therapeutics, Inc.
General ticker "NTLA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6B (TTM average)
Intellia Therapeutics, Inc. follows the US Stock Market performance with the rate: 11.2%.
Estimated limits based on current volatility of 3.7%: low 11.13$, high 11.98$
Factors to consider:
- Total employees count: 377 (-6.5%) as of 2025
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Manufacturing capacity, Commercialization challenges, Capital shortage
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.70$, 17.38$]
- 2026-12-31 to 2027-12-31 estimated range: [5.74$, 15.22$]
Financial Metrics affecting the NTLA estimates:
- Negative: with PPE of -2.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: 69.38 < Shareholder equity ratio, % of 79.73 <= 81.92
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: negative Industry operating income (median)
- Negative: 0 < Industry inventory ratio change (median), % of 0
Short-term NTLA quotes
Long-term NTLA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $36.27MM | $57.88MM | $67.67MM |
| Operating Expenses | $551.57MM | $592.14MM | $508.66MM |
| Operating Income | $-515.29MM | $-534.26MM | $-440.99MM |
| Non-Operating Income | $34.10MM | $15.24MM | $28.30MM |
| R&D Expense | $435.07MM | $466.31MM | $388.86MM |
| Income(Loss) | $-481.19MM | $-519.02MM | $-412.69MM |
| Net Income(Loss)* | $-481.19MM | $-519.02MM | $-306.37MM |
| Stockholders Equity | $1,050.17MM | $871.96MM | $671.39MM |
| Assets | $1,300.98MM | $1,191.02MM | $842.13MM |
| Operating Cash Flow | $-394.09MM | $-348.88MM | $-394.74MM |
| Capital expenditure | $13.98MM | $5.78MM | $5.78MM |
| Investing Cash Flow | $-31.35MM | $125.57MM | $228.03MM |
| Financing Cash Flow | $130.32MM | $185.75MM | $131.49MM |
| Earnings Per Share** | $-5.42 | $-5.25 | $-2.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.